693228-63-6

Basic information

• Product Name: CYC-116
• Synonyms: CYC-116;4-(2-Amino-4-methyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]- 2-Pyrimidinamine;4-(2-amino-4-methylthiazol-5-yl)-N-(4-morpholinophenyl)pyrimidin-2-amine;CYC-1164-(2-amino-4-methylthiazol-5-yl)-N-(4-morpholinophenyl)pyrimidin-2-amine;4-Methyl-5-(2-((4-morpholinophenyl)amino)-pyrimidin-4-yl)thiazol-2-amine
• CAS NO: 693228-63-6
• Molecular Formula: C18H20N6OS
• Molecular Weight: 368.456
• EINECS: -0
• Product Categories: Inhibitor;Inhibitors
• Mol File: 693228-63-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.355
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility: Aqueous Acid, DMSO (Sparingly)
• Water Solubility: Unknown
• CAS DataBase Reference: CYC-116(CAS DataBase Reference)
• NIST Chemistry Reference: CYC-116(693228-63-6)
• EPA Substance Registry System: CYC-116(693228-63-6)

Safety Data

• Hazardous Substances Data: 693228-63-6(Hazardous Substances Data)

Usage

Description

CYC-116 is a small molecule compound that acts as a potent inhibitor of Aurora A/B and VEGFR, with Ki values of 8.0 nM, 9.2 nM, and 44 nM, respectively. It has the potential to be used in various applications due to its ability to target these proteins.

Uses

Used in Pharmaceutical Industry:
CYC-116 is used as a therapeutic agent for targeting Aurora A/B and VEGFR proteins, which are involved in various cellular processes, including cell division and angiogenesis. Its inhibition of these proteins can lead to the suppression of tumor growth and the prevention of blood vessel formation in tumors, making it a potential candidate for cancer treatment.
Used in Drug Development:
CYC-116 is used as a lead compound in drug development for the discovery of new drugs targeting Aurora A/B and VEGFR. Its potent inhibitory activity against these proteins can be further optimized and modified to develop more effective drugs for various diseases, including cancer.
Used in Research:
CYC-116 is used as a research tool to study the role of Aurora A/B and VEGFR in various biological processes. Its ability to inhibit these proteins can help researchers understand their functions and identify potential therapeutic targets for the development of new treatments.
Used in Cancer Therapy:
CYC-116 is used as a cancer therapy agent for the treatment of various types of cancer. Its inhibition of Aurora A/B and VEGFR can lead to the suppression of tumor growth and the prevention of blood vessel formation in tumors, making it a potential treatment option for cancer patients.

Biological Activity

ki: 8.0 and 9.2 nm for aurora a and b, respectivelythe aurora kinases are a family of serine-threonine kinases that interact with components of the mitotic apparatus and that regulate aspects of centrosome maturation, bipolar spindle assembly, chromosome segregation, and cytokinesis. cyc116 has been discoverd as a novel n-phenyl-4-(thiazol-5-yl) pyrimidin-2-amine aurora kinase inhibitor.

in vitro

the anticancer effects of cyc116 were shown to emanate from cell death following mitotic failure and increased polyploidy as a consequence of cellular inhibition of aurora a and b kinases. moreover, cyc116 was also assessed against other kinases [1].

in vivo

preliminary in vivo assessment showed that cyc116 was orally bioavailable and possessed anticancer activity. the mean relative tumor volumes of mice receiving cyc116 at both dose levels were less than those of vehicle-treated mice for the duration of the study period [1].

IC 50

44 and 19 nm respectively for aurora a and b in cancer cells

references

[1] wang s, midgley ca, sca?rou f, grabarek jb, griffiths g, jackson w, kontopidis g, mcclue sj, mcinnes c, meades c, mezna m, plater a, stuart i, thomas mp, wood g, clarke rg, blake dg, zheleva di, lane dp, jackson rc, glover dm, fischer pm. discovery of n-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. j med chem. 2010;53(11):4367-78.

Upstream product

• 314268-63-8 N,N-(4-morpholin-4-yl-phenyl)-guanidine nitrate 
• 507487-90-3 N'-(5-(3-(dimethylamino)acryloyl)-4-methylthiazol-2-yl)-N,N-dimethylformimid amide 
• 2524-67-6 4-morpholino-4-yl-phenylamine 
• 420-04-2 CYANAMID 

Relevant articles and documents

Discovery of N-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors

Through cell-based screening of our kinase-directed compound collection, we discovered that a subset of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amines were potent cytotoxic agents against cancer cell lines, suppressed mitotic histone H3 phosphorylation, and caused aberrant mitotic phenotypes. It was subsequently established that these compounds were in fact potent inhibitors of aurora A and B kinases. It was shown that potency and selectivity of aurora kinase inhibition correlated with the presence of a substituent at the aniline para-position in these compounds. The anticancer effects of lead compound 4-methyl-5-(2-(4- morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine (18; Ki values of 8.0 and 9.2 nM for aurora A and B, respectively) were shown to emanate from cell death following mitotic failure and increased polyploidy as a consequence of cellular inhibition of aurora A and B kinases. Preliminary in vivo assessment showed that compound 18 was orally bioavailable and possessed anticancer activity. Compound 18 (CYC116) is currently undergoing phase I clinical evaluation in cancer patients.

PYRIMIDINE COMPOUNDS

-